United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 500 mg - cefotaxime for injection usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. - lower respiratory tract infections , including pneumonia, caused bystreptococcus pneumoniae (formerlydiplococcus pneumoniae ),streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g.,enterococcus faecalis ),staphylococcus aureus (penicillinase and non-penicillinase producing),escherichia coli ,klebsiella species,haemophilus influenzae (including ampicillin resistant strains),haemophilus parainfluenzae ,proteus mirabilis ,serratia marcescens *,enterobacter species, indole positiveproteus andpseudomonas species (includingp. aeruginosa ). - genitourinary infections . urinary tract infections caused byenterococcus species,staphylococcus epidermidis ,staphylococcus aureus *, (penicillinase and non-penicillinase producing),citrobacter species,enterobacter species,escherichia coli ,kl

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 1 g - cefotaxime for injection, usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes* (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species, haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae , proteus mirabilis , serratia marcescens* , enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). (2) genitourinary infections . urinary tract infections caused by enterococcus species, staphylococcus epidermidis , staphylococcus aureus* , (penicillinase and non-penicillinase producing), citrobacter species, enterobac

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 10 g - cefotaxime for injection, usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes* (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species, haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae , proteus mirabilis , serratia marcescens* , enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). (2) genitourinary infections . urinary tract infections caused by enterococcus species, staphylococcus epidermidis , staphylococcus aureus* , (penicillinase and non-penicillinase producing), citrobacter species, enterobac

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 500 mg - treatment cefotaxime for injection, usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species, haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae , proteus mirabilis , serratia marcescens *, enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). (2) genitourinary infections . urinary tract infections caused by enterococcus species, staphylococcus epidermidis , staphylococcus aureus *, (penicillinase and non-penicillinase producing), citrobacter species,

United States - English - NLM (National Library of Medicine)

sterimax inc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) -

United States - English - NLM (National Library of Medicine)

wockhardt limited - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime sodium 500 mg in 1 ml - - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species , haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae, proteus mirabilis, serratia marcescens*, enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). - genitourinary infections. urinary tract infections caused by enterococcus species, staphylococcus epidermidis, staphylococcus aureus* , (penicillinase and non-penicillinase producing), citrobacter species, enterobacter species, escherichia coli , klebsiella  species, proteus mirabilis, proteus vulgaris*, providencia stuartii, morganella morganii*, providencia rettgeri*, serratia marcescens and pseudomonas s

United States - English - NLM (National Library of Medicine)

hospira, inc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 1 g

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefotaxime sodium 1048.1mg equivalent 1 g cefotaxime (+ 5% overage) - powder for injection - 1 g - active: cefotaxime sodium 1048.1mg equivalent 1 g cefotaxime (+ 5% overage) - cefotaxime is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. · septicaemia. · respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. · urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. · soft tissue infections: cellulitis, peritonitis and wound infections. · bone and joint infections: osteomyelitis, septic arthritis. · obstetric and gynaecological infections: pelvic inflammatory disease. · gonorrhoea: particularly if penicillin-resistant. · other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of cefotaxime prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. cefotaxime should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefotaxime sodium 2096.2mg equivalent 2 g cefotaxime (+ 5% overage) - powder for injection - 2 g - active: cefotaxime sodium 2096.2mg equivalent 2 g cefotaxime (+ 5% overage) - cefotaxime is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. · septicaemia. · respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. · urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. · soft tissue infections: cellulitis, peritonitis and wound infections. · bone and joint infections: osteomyelitis, septic arthritis. · obstetric and gynaecological infections: pelvic inflammatory disease. · gonorrhoea: particularly if penicillin-resistant. · other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of cefotaxime prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. cefotaxime should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefotaxime sodium 524.05mg equivalent to 500 mg cefotaxime (+ 5% overage) - powder for injection - 500 mg - active: cefotaxime sodium 524.05mg equivalent to 500 mg cefotaxime (+ 5% overage) - cefotaxime is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. · septicaemia. · respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. · urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. · soft tissue infections: cellulitis, peritonitis and wound infections. · bone and joint infections: osteomyelitis, septic arthritis. · obstetric and gynaecological infections: pelvic inflammatory disease. · gonorrhoea: particularly if penicillin-resistant. · other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of cefotaxime prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. cefotaxime should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.